

Nicolas J Schlienz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8936023/publications.pdf>

Version: 2024-02-01

29
papers

785
citations

471509

17
h-index

552781

26
g-index

31
all docs

31
docs citations

31
times ranked

1116
citing authors

#	ARTICLE	IF	CITATIONS
1	A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 548-558.	2.9	23
2	Transitioning to Remote Clinic Visits in a Smoking Cessation Trial During the COVID-19 Pandemic: Mixed Methods Evaluation. <i>JMIR Formative Research</i> , 2021, 5, e25541.	1.4	9
3	Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 729800.	2.6	30
4	Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 122, 108205.	1.7	8
5	Urinary Excretion Profile of 11-Nor-9-Carboxy- Δ^9 -Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020, 44, 1-14.	2.8	14
6	Making lemonade from SARS coronavirus-2 lemons: Transitioning a smoking cessation trial to a virtual platform. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108100.	2.8	7
7	Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. <i>Drug and Alcohol Dependence</i> , 2020, 211, 107969.	3.2	47
8	Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2019, 194, 500-517.	3.2	39
9	Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2019, 43, 233-258.	2.8	74
10	Cannabis Withdrawal. , 2019, , 93-102.		2
11	166. Targeting Sleep Disturbance in the Treatment of Cannabis Use Disorders. <i>Biological Psychiatry</i> , 2018, 83, S67.	1.3	0
12	“Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 85-93.	2.9	24
13	Pharmacokinetic Characterization of 11-nor-9-carboxy- Δ^9 -tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. <i>Journal of Analytical Toxicology</i> , 2018, 42, 232-247.	2.8	16
14	The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. <i>Drug and Alcohol Dependence</i> , 2018, 187, 254-260.	3.2	25
15	Event-Related Potentials as Biomarkers of Behavior Change Mechanisms in Substance Use Disorder Treatment. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 30-40.	1.5	25
16	1000 Targeting Sleep in Adults Seeking Treatment for Cannabis Use Disorder. <i>Sleep</i> , 2018, 41, A370-A370.	1.1	0
17	Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. <i>International Review of Psychiatry</i> , 2018, 30, 147-154.	2.8	11
18	Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis. <i>JAMA Network Open</i> , 2018, 1, e184841.	5.9	161

#	ARTICLE	IF	CITATIONS
19	A cognitive model-based approach to testing mechanistic explanations for neuropsychological decrements during tobacco abstinence. <i>Psychopharmacology</i> , 2018, 235, 3115-3124.	3.1	4
20	Co-use of cannabis, tobacco, and alcohol during adolescence: policy and regulatory implications. <i>International Review of Psychiatry</i> , 2018, 30, 226-237.	2.8	30
21	Cannabis Withdrawal: a Review of Neurobiological Mechanisms and Sex Differences. <i>Current Addiction Reports</i> , 2017, 4, 75-81.	3.4	66
22	Probing the Behavioral and Neurophysiological Effects of Acute Smoking Abstinence on Drug and Nondrug Reinforcement During a Cognitive Task. <i>Nicotine and Tobacco Research</i> , 2017, 19, 729-737.	2.6	3
23	Selection criteria limit generalizability of smoking pharmacotherapy studies differentially across clinical trials and laboratory studies: A systematic review on varenicline. <i>Drug and Alcohol Dependence</i> , 2016, 169, 180-189.	3.2	19
24	Psychometric Evaluation of the Substance Use Risk Profile Scale (SURPS) in an Inpatient Sample of Substance Users Using Cue-Reactivity Methodology. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2015, 37, 231-246.	1.2	22
25	The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement. <i>Addictive Behaviors</i> , 2014, 39, 1484-1490.	3.0	25
26	The effects of acute abstinence from smoking and performance-based rewards on performance monitoring. <i>Psychopharmacology</i> , 2013, 229, 701-711.	3.1	18
27	The Effects of Extended Pre-Quit Varenicline Treatment on Smoking Behavior and Short-Term Abstinence: A Randomized Clinical Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 172-180.	4.7	39
28	The effects of varenicline on attention and inhibitory control among treatment-seeking smokers. <i>Psychopharmacology</i> , 2012, 223, 131-138.	3.1	31
29	Hostile attribution biases for relationally provocative situations and event-related potentials. <i>International Journal of Psychophysiology</i> , 2010, 76, 25-33.	1.0	13